



183 99 APR 28 P1 29

College of Medicine
Department of Medicine
Division of Dermatology
956 Court Avenue, Room E332
Memphis, TN 38163
(901) 448-5795 • FAX (901) 448-8284

April 21, 1999

Mr. Igor Cerny, Pharm. D.
Center for Drug Evaluation and Research
HFD-21, Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20557

Dear Mr. Cerny:

This is to confirm that I would like to appear on behalf of the American Academy of Dermatology at the Pharmacy Compounding Advisory Committee meeting which will be held on May 6 and 7, 1999, 8:30 a.m. to 5 p.m. to discuss dinitrochlorobenzene, diphenylcyclopropanone and squaric acid dibutyl ester on behalf of the American Academy of Dermatology. I would hope to be able to talk for 3-5 minutes about my long personal experience with these agents and then be available to try to respond to any concerns raised by the Panel or to answer any questions they might ask.

Also, I will have with me a statement by Mr. Jim Davis, R.Ph. who has been compounding these products for me since 1975. His statement will describe his experience with these products from the perspective of the compounding pharmacist. I appreciate the opportunity to do this.

Sincerely,

E. William Rosenberg, M.D.
Rex A. Amonette Professor,
Department of Medicine (Dermatology),
and Professor, Department of Preventive Medicine

cc: Barbara J. Lowery, Assistant Director
American Academy of Dermatology

98M-0182-

LET3

